Pregnancy and Rheumatic Disease: Planning and Management

Rheumatic diseases intersect with pregnancy in clinically significant ways, affecting both the course of maternal disease and fetal outcomes. Conditions such as lupus, rheumatoid arthritis, and antiphospholipid syndrome require coordinated planning before conception and structured monitoring throughout gestation. The American College of Rheumatology (ACR) and the European Alliance of Associations for Rheumatology (EULAR) have published dedicated guidance addressing medication safety, disease activity targets, and multidisciplinary care frameworks for this population.

Definition and Scope

Pregnancy in the context of rheumatic disease refers to the clinical management of patients who have an established or emerging autoimmune or inflammatory musculoskeletal condition before, during, or after pregnancy. The scope spans preconception counseling, gestational monitoring, medication adjustment, and postpartum management of disease flares.

The regulatory context for rheumatology establishes how drug labeling and prescribing frameworks — governed in the United States by the FDA's Pregnancy and Lactation Labeling Rule (PLLR), which replaced the former letter-category system effective June 30, 2015 — shape prescribing decisions during gestation. Under PLLR, labeling must include structured subsections on pregnancy, lactation, and reproductive potential, providing clinicians with evidence-based risk narratives rather than broad categorical grades.

Conditions most commonly encountered in this clinical intersection include:

1. Systemic lupus erythematosus (SLE)
2. Antiphospholipid syndrome (APS)
3. Rheumatoid arthritis (RA)
4. Sjögren's syndrome
5. Systemic sclerosis (scleroderma)
6. Inflammatory myopathies
7. Vasculitis

Each condition carries distinct risk profiles. SLE, for example, is associated with increased rates of preeclampsia, preterm birth, and fetal growth restriction, particularly when lupus nephritis is active at conception. The rheumatology authority index provides a broader orientation to these overlapping disease domains.

How It Works

Disease management during pregnancy requires balancing maternal disease control against fetal safety. The foundational principle, endorsed by the ACR's 2020 reproductive health guideline, is that uncontrolled disease activity carries higher risk to fetal outcomes than most medications used to treat rheumatic disease.

The management framework proceeds in discrete phases:

Phase 1 — Preconception Planning (6–12 months before conception)
- Disease activity assessment using validated indices (SLEDAI-2K for lupus, DAS28 for RA)
- Medication review and transition off teratogenic agents
- Screening for antiphospholipid antibodies (aPL), anti-Ro/SSA, and anti-La/SSB antibodies
- Optimization of comorbidities including hypertension and renal function

Phase 2 — First Trimester (weeks 1–13)
- Continuation of pregnancy-compatible medications
- Baseline renal and hepatic function panels
- Fetal viability confirmation and dating ultrasound
- Initiation of low-dose aspirin (81 mg) in high-risk patients per the U.S. Preventive Services Task Force (USPSTF) preeclampsia prevention recommendation

Phase 3 — Second and Third Trimester (weeks 14–40)
- Serial fetal echocardiography in anti-Ro/SSA-positive patients between weeks 16 and 26 to monitor for congenital heart block
- Disease activity reassessment at each visit
- Dose adjustments as maternal renal clearance increases

Phase 4 — Postpartum
- Monitoring for disease flare, which is elevated in SLE during the 3–6 months postpartum
- Reassessment of medication regimen for lactation compatibility
- Contraception counseling, particularly in patients with APS or on teratogenic maintenance therapy

Common Scenarios

Scenario A: Lupus and Pregnancy
Active lupus nephritis at conception is associated with significantly worse maternal and fetal outcomes. EULAR guidance recommends conception only after 6 months of sustained remission. Hydroxychloroquine is recommended throughout pregnancy due to evidence supporting reduced flare risk and protective effects against neonatal lupus.

Scenario B: Antiphospholipid Syndrome
Patients with confirmed APS — defined by the Sapporo/Sydney criteria as clinical thrombosis or pregnancy morbidity plus persistent positivity for lupus anticoagulant, anticardiolipin antibodies, or anti-β2 glycoprotein-I antibodies — require anticoagulation management during pregnancy. Those with prior thrombosis receive therapeutic low molecular weight heparin (LMWH); obstetric APS without thrombosis typically receives prophylactic LMWH plus low-dose aspirin.

Scenario C: Rheumatoid Arthritis
RA often improves during pregnancy due to immune tolerance mechanisms, but postpartum flares affect approximately 90% of patients who experienced remission during gestation, according to data cited in the ACR 2020 Reproductive Health Guideline. TNF inhibitors such as certolizumab pegol have been used during pregnancy; unlike other TNF inhibitors, certolizumab lacks an Fc region and therefore has minimal placental transfer, a pharmacologic distinction with clinical relevance.

Scenario D: Neonatal Lupus
Anti-Ro/SSA antibody-positive mothers face a 1–3% risk of fetal congenital heart block per the Research Registry for Neonatal Lupus (RRNL) data. Incomplete heart block detected before week 30 may be treated with fluorinated corticosteroids, though evidence for reversal is limited.

Decision Boundaries

The distinction between conditions that are generally safe to manage with standard-of-care medications during pregnancy and those requiring complete regimen restructuring is clinically critical.

Medications generally considered compatible with pregnancy (per PLLR labeling and ACR guidance):
- Hydroxychloroquine
- Sulfasalazine (with folate supplementation)
- Azathioprine
- Certolizumab pegol
- Low-dose corticosteroids (prednisone ≤10 mg/day)

Medications requiring discontinuation before conception:
- Methotrexate — teratogenic; must be discontinued at least 3 months before conception per ACR guidance
- Mycophenolate mofetil — associated with a documented 23–27% rate of spontaneous abortion and specific fetal malformations per the FDA's Risk Evaluation and Mitigation Strategy (REMS) program
- Leflunomide — teratogenic; requires cholestyramine washout before pregnancy
- Cyclophosphamide — contraindicated in the first trimester; used only for life-threatening disease in later trimesters

Understanding inflammation and rheumatic disease mechanisms is foundational to interpreting why some agents carry gestational risk while others are protective. For broader disease-specific guidance, managing rheumatoid arthritis and living with lupus provide condition-level context.

The multidisciplinary framework — involving rheumatology, maternal-fetal medicine, cardiology (for cardiac manifestations), and nephrology (for renal lupus) — is not optional for complex cases. EULAR's 2017 Recommendations for Women's Health and Management of Family Planning provide a structured benchmark against which care pathways can be measured.

References

• American College of Rheumatology — 2020 Guideline for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases
• EULAR Recommendations for Women's Health and the Management of Family Planning, Assisted Reproduction, Pregnancy and Menopause in Patients with Systemic Lupus Erythematosus and/or Antiphospholipid Syndrome (2017)
• U.S. Food and Drug Administration — Pregnancy and Lactation Labeling Rule (PLLR)
• U.S. Preventive Services Task Force — Low-Dose Aspirin Use to Prevent Preeclampsia and Related Morbidity and Mortality
• FDA Risk Evaluation and Mitigation Strategy (REMS) — Mycophenolate
• Research Registry for Neonatal Lupus — NYU Langone Health

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)